晚期进行性甲状腺髓样癌患者的肽受体放射性核素治疗:疗效、安全性和生存预测因子

IF 1 4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuklearmedizin-nuclear Medicine Pub Date : 2023-03-30 DOI:10.1055/s-0043-1766219

Q. X. Liu, H. R. Kulkarni, T. Z. Zhao, C. Schuchardt, X. Chen, Z. H. Zhu, J. Zhang, R. P. Baum

{"title":"晚期进行性甲状腺髓样癌患者的肽受体放射性核素治疗:疗效、安全性和生存预测因子","authors":"Q. X. Liu, H. R. Kulkarni, T. Z. Zhao, C. Schuchardt, X. Chen, Z. H. Zhu, J. Zhang, R. P. Baum","doi":"10.1055/s-0043-1766219","DOIUrl":null,"url":null,"abstract":"Ziel/Aim Metastatic medullary thyroid carcinoma (MTC) is often has a rapid disease progression and poor prognosis with few therapeutic options available. Peptide Receptor Radionuclide Therapy (PRRT) has demonstrated success in the management of gastroenteropancreatic neuroendocrine tumors and has also been used to treat MTC. The objective of this study was to assess the safety and efficacy of PRRT in patients with advanced, progressive MTC, to determine survival and potential predictors of survival.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"16 1","pages":"0"},"PeriodicalIF":1.0000,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Peptide Receptor Radionuclide Therapy in Patients with Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety and Survival Predictors\",\"authors\":\"Q. X. Liu, H. R. Kulkarni, T. Z. Zhao, C. Schuchardt, X. Chen, Z. H. Zhu, J. Zhang, R. P. Baum\",\"doi\":\"10.1055/s-0043-1766219\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ziel/Aim Metastatic medullary thyroid carcinoma (MTC) is often has a rapid disease progression and poor prognosis with few therapeutic options available. Peptide Receptor Radionuclide Therapy (PRRT) has demonstrated success in the management of gastroenteropancreatic neuroendocrine tumors and has also been used to treat MTC. The objective of this study was to assess the safety and efficacy of PRRT in patients with advanced, progressive MTC, to determine survival and potential predictors of survival.\",\"PeriodicalId\":19238,\"journal\":{\"name\":\"Nuklearmedizin-nuclear Medicine\",\"volume\":\"16 1\",\"pages\":\"0\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2023-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuklearmedizin-nuclear Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0043-1766219\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuklearmedizin-nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0043-1766219","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

摘要

转移性甲状腺髓样癌(MTC)通常病情进展迅速，预后差，治疗选择很少。肽受体放射性核素疗法(PRRT)在胃肠胰神经内分泌肿瘤的治疗中已被证明是成功的，也已被用于治疗MTC。本研究的目的是评估PRRT在晚期进展性MTC患者中的安全性和有效性，以确定生存和潜在的生存预测因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Peptide Receptor Radionuclide Therapy in Patients with Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety and Survival Predictors

Ziel/Aim Metastatic medullary thyroid carcinoma (MTC) is often has a rapid disease progression and poor prognosis with few therapeutic options available. Peptide Receptor Radionuclide Therapy (PRRT) has demonstrated success in the management of gastroenteropancreatic neuroendocrine tumors and has also been used to treat MTC. The objective of this study was to assess the safety and efficacy of PRRT in patients with advanced, progressive MTC, to determine survival and potential predictors of survival.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nuklearmedizin-nuclear Medicine 医学-核医学

CiteScore

1.70

自引率

13.30%

发文量

267

审稿时长

>12 weeks

期刊介绍： Als Standes- und Fachorgan (Organ von Deutscher Gesellschaft für Nuklearmedizin (DGN), Österreichischer Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (ÖGN), Schweizerischer Gesellschaft für Nuklearmedizin (SGNM, SSNM)) von hohem wissenschaftlichen Anspruch befasst sich die CME-zertifizierte Nuklearmedizin/ NuclearMedicine mit Diagnostik und Therapie in der Nuklearmedizin und dem Strahlenschutz: Originalien, Übersichtsarbeiten, Referate und Kongressberichte stellen aktuelle Themen der Diagnose und Therapie dar. Ausführliche Berichte aus den DGN-Arbeitskreisen, Nachrichten aus Forschung und Industrie sowie Beschreibungen innovativer technischer Geräte, Einrichtungen und Systeme runden das Konzept ab. Die Abstracts der Jahrestagungen dreier europäischer Fachgesellschaften sind Bestandteil der Kongressausgaben. Nuklearmedizin erscheint regelmäßig mit sechs Ausgaben pro Jahr und richtet sich vor allem an Nuklearmediziner, Radiologen, Strahlentherapeuten, Medizinphysiker und Radiopharmazeuten.